GleamWall
中文EN

PPCB Propanc Biopharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1517681 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY64.3%
TTM EPS YoY115.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-211.0%
ROA-159.8%
ROIC (approx.)-168.8%
Asset turnover—

Leverage & solvency

Liabilities / assets31.5%
Debt / equity0.00x
Current ratio2.47x
Interest coverage-154.29x

Cash quality & payout

Operating cash flow / net income0.25x
Accruals ratio-119.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue—————
R&D expense$625,477$223,721$248,102$247,919$256,052
SG&A expense$670,607$108,950$1.25M$1.50M$1.71M
Operating income-$18.19M-$57.28M-$1.54M-$1.78M-$1.99M
Interest expense$430,539$563,757$665,841$532,821$568,798
Pretax income-$18.86M-$58.92M-$1.95M-$2.79M-$2.71M
Income tax——-$129,132-$129,841-$54,977
Net income-$18.86M-$58.92M-$1.82M-$2.66M-$2.66M
EBITDA-$18.18M—-$1.54M-$1.77M-$1.99M
EPS (basic)-17.62-371.22-1,420.53-1.80-49.23
EPS (diluted)-17.62-371.22-1,420.53-1.80-49.23
Weighted avg. shares (diluted)1.12M158,7271,4171.74M68,219
Balance sheet
Cash & equivalents$832,006$12,088$21,085$10,047$4,067
Current assets$8.54M$8.35M$25,441$19,039$15,030
PP&E, net$3,915——$302$2,023
Total assets$12.78M$19.63M$72,365$60,328$81,651
Current liabilities$3.35M$5.58M$3.79M$3.16M$3.06M
Long-term debt—$537,921$399,325$390,539$926,438
Total debt—$537,921$399,325$390,539$926,438
Total liabilities$3.38M$5.73M$3.85M$3.18M$3.11M
Shareholders' equity$9.40M$13.91M-$3.78M-$3.12M-$3.02M
Net debt—$525,833$378,240$380,492$922,371
Shares outstanding331,083464,4717,9806.03M220,351
Cash flow statement
Operating cash flow-$5.68M-$405,168-$935,118-$1.11M-$1.44M
Capital expenditure$4,933————
Free cash flow-$5.69M————
Investing cash flow-$4,933————
Financing cash flow$6.46M$490,756$941,894$1.11M$1.49M
Depreciation & amortization$997—$297$1,665$1,993
Stock-based compensation$8.50M$4.62M—$2,408$72,513

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.